News and Deals
Linklaters advises redalpine on Helical’s new fundraising round to accelerate AI-driven drug discovery
Press Contact
Véronique Cioli
Head of Marketing Europe
+35226088226
veronique.cioli@linklaters.com
Contact Us
LinklatersMarketingL@linklaters.com
Previous Campaigns
Linklaters has advised redalpine, a leading multi-stage venture capital investor, as lead investor on the fundraising of Helical, a Luxembourg-based start-up developing a virtual artificial intelligence (AI) laboratory designed to speed up and improve the reliability of drug discovery, alongside a syndicate of international investors.
Headquartered in Luxembourg and co-founded by three Luxembourgish entrepreneurs, Helical aims to build a virtual AI laboratory capable of integrating and analysing complex experimental and clinical data to accelerate early-stage drug development.
The fundraising will support Helical in scaling its AI-driven pharmaceutical research platform, designed to help pharmaceutical and biotechnology companies identify and validate new drug candidates more efficiently, facilitating experimental processes with AI models running in-silico experiments at scale.
The Linklaters Luxembourg team advising redalpine was led by Luxembourg Corporate M&A Partner Rémy Bonneau, with Managing Associate Colas Surot and Associate Lucas Hieronimus. The team also included Litigation, Arbitration and Investigation Counsel Louis-Eudes Giroux, with Junior Associate Marie Favier, Employment Counsel Marie Sinniger and Real Estate Counsel Anton Cox.
Rémy Bonneau, Partner at Linklaters Luxembourg, added:
“We were delighted to advise redalpine on this strategic fundraising for Helical. This mandate highlights the depth of our transactional, cross-practice capabilities in Luxembourg and our leading market position in the technology sector and venture capital ecosystem.”